Evidence map›Paper›PMID 27082897›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2016

GPR119 Agonist AS1269574 Activates TRPA1 Cation Channels to Stimulate GLP-1 Secretion.

Oleg G Chepurny, George G Holz, Michael W Roe, Colin A Leech

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Structure of human GPR119-GFrontiers in pharmacology · 2024
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. [Molecular pharmaceutics · 2020
    Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Oleg G ChepurnyDepartments of Medicine (O.G.C., G.G.H., M.W.R., C.A.L.), Pharmacology (G.G.H.), and Cell and Developmental Biology (M.W.R.), State University of New York, and Upstate Medical University, Syracuse, New York 13210.
George G HolzDepartments of Medicine (O.G.C., G.G.H., M.W.R., C.A.L.), Pharmacology (G.G.H.), and Cell and Developmental Biology (M.W.R.), State University of New York, and Upstate Medical University, Syracuse, New York 13210.
Michael W RoeDepartments of Medicine (O.G.C., G.G.H., M.W.R., C.A.L.), Pharmacology (G.G.H.), and Cell and Developmental Biology (M.W.R.), State University of New York, and Upstate Medical University, Syracuse, New York 13210.
Colin A LeechDepartments of Medicine (O.G.C., G.G.H., M.W.R., C.A.L.), Pharmacology (G.G.H.), and Cell and Developmental Biology (M.W.R.), State University of New York, and Upstate Medical University, Syracuse, New York 13210.
SUNY Upstate Medical University · US

Funding

Molecular Basis of Antidiabetogenic Hormone ActionR01DK069575 · NIDDK · UPSTATE MEDICAL UNIVERSITY · PI HOLZ, GEORGE G · 2007 to 2017
$2.9M
Molecular Physiology of Store-Dependant Calcium Entry in Pancreatic Beta Cells.R01DK092616 · NIDDK · UPSTATE MEDICAL UNIVERSITY · PI ROE, MICHAEL WILLIAM · 2012 to 2015
$1.9M
NIDDK NIH HHS R01 DK069575NIDDK NIH HHS R01 DK092616
6 · The paper itself

Abstract

GPR119 is a G protein-coupled receptor expressed on intestinal L cells that synthesize and secrete the blood glucose-lowering hormone glucagon-like peptide-1 (GLP-1). GPR119 agonists stimulate the release of GLP-1 from L cells, and for this reason there is interest in their potential use as a new treatment for type 2 diabetes mellitus. AS1269574 is one such GPR119 agonist, and it is the prototype of a series of 2,4,6 trisubstituted pyrimidines that exert positive glucoregulatory actions in mice. Here we report the unexpected finding that AS1269574 stimulates GLP-1 release from the STC-1 intestinal cell line by directly promoting Ca(2+) influx through transient receptor potential ankyrin 1 (TRPA1) cation channels. These GPR119-independent actions of AS1269574 are inhibited by TRPA1 channel blockers (AP-18, A967079, HC030031) and are not secondary to intracellular Ca(2+) release or cAMP production. Patch clamp studies reveal that AS1269574 activates an outwardly rectifying membrane current with properties expected of TRPA1 channels. However, the TRPA1 channel-mediated action of AS1269574 to increase intracellular free calcium concentration is not replicated by GPR119 agonists (AR231453, oleoylethanolamide) unrelated in structure to AS1269574. Using human embryonic kidney-293 cells expressing recombinant rat TRPA1 channels but not GPR119, direct TRPA1 channel activating properties of AS1269574 are validated. Because we find that AS1269574 also acts in a conventional GPR119-mediated manner to stimulate proglucagon gene promoter activity in the GLUTag intestinal L cell line, new findings reported here reveal the surprising capacity of AS1269574 to act as a dual agonist at two molecular targets (GPR119/TRPA1) important to the control of L-cell function and type 2 diabetes mellitus drug discovery research.

Indexed as

AnimalsCalciumCyclic AMPCyclic AMP-Dependent Protein KinasesCymenesEndoplasmic ReticulumEthanolaminesGene Expression RegulationGlucagonGlucagon-Like Peptide 1HEK293 CellsHumansIon Channel GatingIsothiocyanatesLuciferasesMonoterpenes2-(2-(4-bromophenyl)-6-methylpyrimidin-4-yl)aminoethanol2,3,4-tri-O-acetylarabinopyranosyl isothiocyanateCalciumcarvacrolCyclic AMPCyclic AMP-Dependent Protein KinasesCymenesEthanolaminesGlucagonGlucagon-Like Peptide 1IsothiocyanatesLuciferasesMonoterpenesMutant ProteinsProglucagonPyrimidinesReceptors, G-Protein-CoupledRecombinant ProteinsTRPA1 Cation Channel

Identifiers

PMID27082897
PMCPMC4884340
OpenAlexW2339594818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.